Abstract
Meta-analysis can be applied to study the effectiveness of the summary estimates for experimental papers, producing objective and unbiased results. We investigated the effects of phosphoinositide-3-kinase (PI3K) on the inflammatory profile in allergic mouse models, which are currently under development in signal transduction materials. PubMed, EMBASE and Web of Science databases were searched for relevant literature using the search terms “ PI3K inhibitor” and “allergy” or “asthma”. Cochrane Review Manager and R were used for handling continuous variables. The primary outcomes of the inflammatory profile were divided into cell counts and inflammatory cytokines. We used a random effects model to draw a forest plot. Through the database search and subsequent selection, 17 articles were identified. Regarding the cell counts, both the PI3K pan-inhibitors and PI3K-δ inhibitors effectively reduced the total cell counts, eosinophils, neutrophils and lymphocytes. In contrast to PI3K-δ inhibitors, PI3K pan-inhibitors effectively reduced macrophages. Regarding the inflammatory cytokines, PI3K pan-inhibitors and PI3K-δ inhibitors effectively reduced total IgE, IL-4, IL-5, IL-13, TNF-α, IL-1β, VEGF and had no effect on IL-6. Compared to the PI3K pan-inhibitors, which block all pathways, selective PI3K-δ inhibitors are expected to be relatively less toxic. Regarding the efficacy, PI3K-δ inhibitors have at least the same or better efficacy than PI3K pan-inhibitors in effector cells and inflammatory mediators.
Highlights
We have found that most of the major inflammatory actions associated with PI3K signalling, known as the critical pathway, are mediated by the delta isotype pathway
PI3K-δ inhibitors had no effect on eotaxin
Summary
This study was the subject of IRB exemption from Chonbuk National University Hospital, and followed the PRISMA guidelines[6]. PubMed, EMBASE, Web of Science, Google Scholar, and Cochrane Library databases were included in the literature search. The search term in Medline was: (PI3K inhibitor OR idelalisib) AND (asthma OR allergic OR allergy). All the PI3K pan-inhibitor and PI3K-δ selective inhibitor found in our search criteria. Similar search terms were used for the four other databases. Two authors independently performed the literature search and the published studies identified in the search results included data up to July 2019
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
